International team develops blood test for early breast cancer detection and recurrence risk

Researchers at the Weizmann Institute and international collaborators have developed a blood test that detects early-stage breast cancer and predicts recurrence risk post-treatment. The test's sensitivity and specificity are not yet disclosed, and clinical validation remains pending. If confirmed, this could shift screening paradigms and improve post-treatment monitoring.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works